408 related articles for article (PubMed ID: 17392452)
1. The vanilloid receptor TRPV1 is tonically activated in vivo and involved in body temperature regulation.
Gavva NR; Bannon AW; Surapaneni S; Hovland DN; Lehto SG; Gore A; Juan T; Deng H; Han B; Klionsky L; Kuang R; Le A; Tamir R; Wang J; Youngblood B; Zhu D; Norman MH; Magal E; Treanor JJ; Louis JC
J Neurosci; 2007 Mar; 27(13):3366-74. PubMed ID: 17392452
[TBL] [Abstract][Full Text] [Related]
2. Antihyperalgesic effects of (R,E)-N-(2-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)-acrylamide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats.
Lehto SG; Tamir R; Deng H; Klionsky L; Kuang R; Le A; Lee D; Louis JC; Magal E; Manning BH; Rubino J; Surapaneni S; Tamayo N; Wang T; Wang J; Wang J; Wang W; Youngblood B; Zhang M; Zhu D; Norman MH; Gavva NR
J Pharmacol Exp Ther; 2008 Jul; 326(1):218-29. PubMed ID: 18420600
[TBL] [Abstract][Full Text] [Related]
3. Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade.
Gavva NR; Bannon AW; Hovland DN; Lehto SG; Klionsky L; Surapaneni S; Immke DC; Henley C; Arik L; Bak A; Davis J; Ernst N; Hever G; Kuang R; Shi L; Tamir R; Wang J; Wang W; Zajic G; Zhu D; Norman MH; Louis JC; Magal E; Treanor JJ
J Pharmacol Exp Ther; 2007 Oct; 323(1):128-37. PubMed ID: 17652633
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of peripherally restricted transient receptor potential vanilloid 1 (TRPV1) antagonists.
Tamayo N; Liao H; Stec MM; Wang X; Chakrabarti P; Retz D; Doherty EM; Surapaneni S; Tamir R; Bannon AW; Gavva NR; Norman MH
J Med Chem; 2008 May; 51(9):2744-57. PubMed ID: 18386885
[TBL] [Abstract][Full Text] [Related]
5. 7-tert-Butyl-6-(4-chloro-phenyl)-2-thioxo-2,3-dihydro-1H-pyrido[2,3-d]pyrimidin-4-one, a classic polymodal inhibitor of transient receptor potential vanilloid type 1 with a reduced liability for hyperthermia, is analgesic and ameliorates visceral hypersensitivity.
Nash MS; McIntyre P; Groarke A; Lilley E; Culshaw A; Hallett A; Panesar M; Fox A; Bevan S
J Pharmacol Exp Ther; 2012 Aug; 342(2):389-98. PubMed ID: 22566669
[TBL] [Abstract][Full Text] [Related]
6. Nonthermal activation of transient receptor potential vanilloid-1 channels in abdominal viscera tonically inhibits autonomic cold-defense effectors.
Steiner AA; Turek VF; Almeida MC; Burmeister JJ; Oliveira DL; Roberts JL; Bannon AW; Norman MH; Louis JC; Treanor JJ; Gavva NR; Romanovsky AA
J Neurosci; 2007 Jul; 27(28):7459-68. PubMed ID: 17626206
[TBL] [Abstract][Full Text] [Related]
7. Effects of the transient receptor potential vanilloid 1 antagonist A-425619 on body temperature and thermoregulation in the rat.
Mills C; McMackin M; Jaffe R; Yu J; Zininberg E; Slee D; Gogas K; Bradbury M
Neuroscience; 2008 Sep; 156(1):165-74. PubMed ID: 18706981
[TBL] [Abstract][Full Text] [Related]
8. TRPV1 antagonists that cause hypothermia, instead of hyperthermia, in rodents: Compounds' pharmacological profiles, in vivo targets, thermoeffectors recruited and implications for drug development.
Garami A; Pakai E; McDonald HA; Reilly RM; Gomtsyan A; Corrigan JJ; Pinter E; Zhu DXD; Lehto SG; Gavva NR; Kym PR; Romanovsky AA
Acta Physiol (Oxf); 2018 Jul; 223(3):e13038. PubMed ID: 29352512
[TBL] [Abstract][Full Text] [Related]
9. The chimeric approach reveals that differences in the TRPV1 pore domain determine species-specific sensitivity to block of heat activation.
Papakosta M; Dalle C; Haythornthwaite A; Cao L; Stevens EB; Burgess G; Russell R; Cox PJ; Phillips SC; Grimm C
J Biol Chem; 2011 Nov; 286(45):39663-72. PubMed ID: 21911503
[TBL] [Abstract][Full Text] [Related]
10. Hyperthermia induced by transient receptor potential vanilloid-1 (TRPV1) antagonists in human clinical trials: Insights from mathematical modeling and meta-analysis.
Garami A; Shimansky YP; Rumbus Z; Vizin RCL; Farkas N; Hegyi J; Szakacs Z; Solymar M; Csenkey A; Chiche DA; Kapil R; Kyle DJ; Van Horn WD; Hegyi P; Romanovsky AA
Pharmacol Ther; 2020 Apr; 208():107474. PubMed ID: 31926897
[TBL] [Abstract][Full Text] [Related]
11. Body-temperature maintenance as the predominant function of the vanilloid receptor TRPV1.
Gavva NR
Trends Pharmacol Sci; 2008 Nov; 29(11):550-7. PubMed ID: 18805596
[TBL] [Abstract][Full Text] [Related]
12. Pharmacology of modality-specific transient receptor potential vanilloid-1 antagonists that do not alter body temperature.
Reilly RM; McDonald HA; Puttfarcken PS; Joshi SK; Lewis L; Pai M; Franklin PH; Segreti JA; Neelands TR; Han P; Chen J; Mantyh PW; Ghilardi JR; Turner TM; Voight EA; Daanen JF; Schmidt RG; Gomtsyan A; Kort ME; Faltynek CR; Kym PR
J Pharmacol Exp Ther; 2012 Aug; 342(2):416-28. PubMed ID: 22570364
[TBL] [Abstract][Full Text] [Related]
13. The sympathetic nervous system is controlled by transient receptor potential vanilloid 1 in the regulation of body temperature.
Alawi KM; Aubdool AA; Liang L; Wilde E; Vepa A; Psefteli MP; Brain SD; Keeble JE
FASEB J; 2015 Oct; 29(10):4285-98. PubMed ID: 26136480
[TBL] [Abstract][Full Text] [Related]
14. AMG 9810 [(E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)acrylamide], a novel vanilloid receptor 1 (TRPV1) antagonist with antihyperalgesic properties.
Gavva NR; Tamir R; Qu Y; Klionsky L; Zhang TJ; Immke D; Wang J; Zhu D; Vanderah TW; Porreca F; Doherty EM; Norman MH; Wild KD; Bannon AW; Louis JC; Treanor JJ
J Pharmacol Exp Ther; 2005 Apr; 313(1):474-84. PubMed ID: 15615864
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of transient receptor vanilloid one (TRPV1) antagonists in acid-induced excitation of esophageal vagal afferent fibers of rats.
Peles S; Medda BK; Zhang Z; Banerjee B; Lehmann A; Shaker R; Sengupta JN
Neuroscience; 2009 Jun; 161(2):515-25. PubMed ID: 19324074
[TBL] [Abstract][Full Text] [Related]
16. In vitro characterization of the thermoneutral transient receptor potential vanilloid-1 (TRPV1) inhibitor GRTE16523.
Damann N; Bahrenberg G; Stockhausen H; Habermann CJ; Lesch B; Frank-Foltyn R; Lee J; Ann J; Christoph T
Eur J Pharmacol; 2020 Mar; 871():172934. PubMed ID: 31954706
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans.
Gavva NR; Treanor JJ; Garami A; Fang L; Surapaneni S; Akrami A; Alvarez F; Bak A; Darling M; Gore A; Jang GR; Kesslak JP; Ni L; Norman MH; Palluconi G; Rose MJ; Salfi M; Tan E; Romanovsky AA; Banfield C; Davar G
Pain; 2008 May; 136(1-2):202-10. PubMed ID: 18337008
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationships of vanilloid receptor agonists for arteriolar TRPV1.
Czikora Á; Lizanecz E; Bakó P; Rutkai I; Ruzsnavszky F; Magyar J; Pórszász R; Kark T; Facskó A; Papp Z; Édes I; Tóth A
Br J Pharmacol; 2012 Mar; 165(6):1801-1812. PubMed ID: 21883148
[TBL] [Abstract][Full Text] [Related]
19. Effect of increasing temperature on TRPV1-mediated responses in isolated rat pulmonary sensory neurons.
Ni D; Lee LY
Am J Physiol Lung Cell Mol Physiol; 2008 Mar; 294(3):L563-71. PubMed ID: 18178674
[TBL] [Abstract][Full Text] [Related]
20. Amelioration of neuropathic pain by novel transient receptor potential vanilloid 1 antagonist AS1928370 in rats without hyperthermic effect.
Watabiki T; Kiso T; Kuramochi T; Yonezawa K; Tsuji N; Kohara A; Kakimoto S; Aoki T; Matsuoka N
J Pharmacol Exp Ther; 2011 Mar; 336(3):743-50. PubMed ID: 21098091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
